This paper forms part of the supplement entitled ‘Update on endothelin-related diseases’. It is related to discussions at the workshop ‘Endothelin-related diseases’ at 42nd Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI) in Geneva, Switzerland, 26–29 March 2008. The workshop and the production costs of the present supplement were supported with an unrestricted Educational Grant from Encysive Pharmaceuticals Inc. In June 2008, Encysive was acquired by Pfizer Inc who funded the publication and formatting costs of this supplement. Tracy Johnson formatted the manuscript according to the journal’s style requirements.
Endothelin receptor antagonism and cancer
Article first published online: 24 MAR 2009
© 2009 The Authors. Journal Compilation © 2009 Blackwell Publishing Ltd
European Journal of Clinical Investigation
Special Issue: Update on endothelin-related diseases
Volume 39, Issue Supplement s2, pages 74–77, June 2009
How to Cite
Bhalla, A., Haque, S., Taylor, I., Winslet, M. and Loizidou, M. (2009), Endothelin receptor antagonism and cancer. European Journal of Clinical Investigation, 39: 74–77. doi: 10.1111/j.1365-2362.2009.02123.x
- Issue published online: 24 MAR 2009
- Article first published online: 24 MAR 2009
- Received 8 January 2009; accepted 27 January 2009
Vol. 39, Issue 7, 630, Article first published online: 5 JUN 2009
- endothelin receptor antagonism;
The endothelin peptides have an important role in the cancer-stromal interactions that promote tumour growth. Endothelin-1 (ET-1), clinically the most investigated endothelin, is a vital agent in the growth and progression of several tumours including prostate, ovarian, colorectal, bladder, breast and lung carcinomas. ET-1 exerts its effects through the activation of two distinct receptors, ETA and ETB. Once activated, these receptors transmit signals via numerous intracellular signalling pathways. The effects of ET receptor stimulation in cancer cells or cancer-associated cells include proliferation, resistance to apoptosis, angiogenesis, migration and subsequent invasion. At present, the manipulation of the endothelin axis within the pre-clinical setting is the subject of intense investigation. Recent studies into ET receptor antagonism have produced interesting results highlighting the fact that these receptors may provide novel targets for a new generation of chemotherapeutic agents in a variety of cancers.